NCT04667013View on ClinicalTrials.gov

A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

August 30, 2026

Conditions
Healthy
Interventions
DRUG

Tetramethylpyrazine nitrone (TBN) tablet / Placebo

Subjects will be administered multiple oral doses of TBN or matching placebo tablets twice a day for 6 consecutive days and a last dose in the morning of Day 7.

All Listed Sponsors
lead

Guangzhou Magpie Pharmaceuticals Co., Ltd.

INDUSTRY